Denali Therapeutics Inc’s recent filing unveils that its Director SATO VICKI L unloaded Company’s shares for reported $64403.0 on Jan 02 ’25. In the deal valued at $20.91 per share,3,080 shares were sold. As a result of this transaction, SATO VICKI L now holds 107,976 shares worth roughly $2.14 million.
Then, VICKI LEE SATO bought 6,160 shares, generating $125,541 in total proceeds.
Before that, STEVE KROGNES bought 30,000 shares. Denali Therapeutics Inc shares valued at $607,200 were divested by the Director at a price of $20.24 per share.
William Blair initiated its Denali Therapeutics Inc [DNLI] rating to an Outperform in a research note published recently. A number of analysts have revised their coverage, including Stifel’s analysts, who increased its forecast for the stock in mid December from “a Hold” to “a Buy”. Cantor Fitzgerald revised its rating on October 07, 2024. It rated DNLI as “a Neutral” which previously was an “an Overweight”.
Price Performance Review of DNLI
On Monday, Denali Therapeutics Inc [NASDAQ:DNLI] saw its stock fall -6.77% to $19.82. Over the last five days, the stock has lost -3.83%. Denali Therapeutics Inc shares have fallen nearly -2.75% since the year began. Nevertheless, the stocks have fallen -2.22% over the past one year. While a 52-week high of $33.33 was reached on 01/03/25, a 52-week low of $14.56 was recorded on 01/06/25. SMA at 50 days reached $24.74, while 200 days put it at $23.09.
Levels Of Support And Resistance For DNLI Stock
The 24-hour chart illustrates a support level at 19.24, which if violated will result in even more drops to 18.65. On the upside, there is a resistance level at 20.90. A further resistance level may holdings at 21.97. The Relative Strength Index (RSI) on the 14-day chart is 31.94, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.58, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 97.96%. Stochastics %K at 18.37% indicates the stock is a buying.
How much short interest is there in Denali Therapeutics Inc?
A steep rise in short interest was recorded in Denali Therapeutics Inc stocks on 2024-12-13, growing by 0.37 million shares to a total of 7.46 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 7.1 million shares. There was a rise of 4.9%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 13, 2023 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $32 price target.
